AssayIndex

SWB-2311-B4884

Tirzepatide · 15 mg declared · Shanghai Wibson Biotechnology Co., Ltd. · manufactured 17 Nov 2023

CHARACTERISED
Lot code
SWB-2311-B4884
Supplier
SWB — Shanghai Wibson Biotechnology Co., Ltd.
Compound
Tirzepatide
Compound class
Incretin analogues and co-agonists
Declared label claim
15mg
Manufacture date
17 Nov 2023
Index quarter
2024-Q2
Independent assays
4
Laboratories involved
Janoshik, Medutest
Provenance mix
Supplier-supplied ×3 · Laboratory-retained ×1
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 4
Median purity 96.88% n=4
Spread (max − min) 0.94pp n=4
Standard deviation 0.450pp n=4
95.696.497.197.998.799.5100.3This lot (SWB-2311-B4884)This lot (SWB-2311-B4884): Q1 96.59, median 96.88, Q3 97.23, n=4n=4All TirzepatideAll Tirzepatide: Q1 97.85, median 98.44, Q3 99.08, n=576outlier 95.92n=576 Purity (% area)
Figure 1. This lot's independent purity results against the whole Tirzepatide record set in the index. The vertical line is the index acceptance specification for the incretin analogues and co-agonists class, 97.0 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 4

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2024-004857SWB-2311-B4884Janoshik2024-Q297.156.84Supplier-supplied1MARGINAL
AX-2024-004858SWB-2311-B4884Janoshik2024-Q296.556.8294.6Laboratory-retained1FAIL
AX-2024-004859SWB-2311-B4884Janoshik2024-Q297.497.7498.6Supplier-supplied1MARGINAL
AX-2024-004860SWB-2311-B4884Medutest2024-Q296.617.2697.2Supplier-supplied1FAIL
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
Janoshik397.15, 96.55, 97.4997.1530min+0.0097.15
Medutest196.6196.6125min+0.0896.53

This lot contributes 1 paired comparison to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)97.3097.15divergence +0.42 pp vs batch median
Total impurities (% area)not stated2.85
Largest single impurity (% area)not stated1.64
Water (%)not stated6.84
Counter-ion (%)5.95.37
Peptide content (%w/w)96.9not determined
Endotoxin (EU/mg)not stated0.50
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
[D-Aib13]-diastereomer4 / 40.750.07–1.64
des-Aib2 analogue4 / 40.140.06–0.24
C20 diacid mono-amide4 / 40.330.12–0.51
Met(O) sulfoxide (+16 Da)4 / 40.770.05–1.52
truncated (3-39)2 / 40.710.66–0.75
tirzepatide dimer2 / 40.030.03–0.03
des-Gly deletion (−57 Da)2 / 40.970.96–0.98
trifluoroacetyl adduct (+96 Da)2 / 40.300.30–0.30
Section 7

What this rollup does not establish